Semaglutide
Semaglutide (GLP-1 Receptor Agonist)
GLP-1 Peptide for Weight Loss
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes. It mimics the natural GLP-1 hormone that is released in the gut in response to eating. By activating GLP-1 receptors, semaglutide increases insulin secretion, decreases glucagon secretion, and slows gastric emptying, which leads to reduced appetite and caloric intake.
Semaglutide has gained significant attention for its effectiveness in promoting weight loss. In clinical trials, participants using semaglutide lost significantly more weight compared to placebo groups. It is marketed under brand names such as Ozempic (for diabetes) and Wegovy (for weight management).
The peptide works by targeting areas of the brain that regulate appetite and food intake, leading to a feeling of fullness and reduced hunger. This mechanism, combined with its effects on blood sugar regulation, makes it a powerful tool for weight management in individuals with obesity or overweight conditions.
Research Supply
Source high-purity Semaglutide for your research
Dosage Guide
Route: Subcutaneous injection, once weekly
Dosing Schedule
| Period | Dose |
|---|---|
| Weeks 1-4 | 0.25 mg |
| Weeks 5-8 | 0.5 mg |
| Weeks 9-12 | 1.0 mg |
| Weeks 13-16 | 1.7 mg |
| Week 17+ | 2.4 mg (maintenance) |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 0.25 mg | 0.1 mL | 10 units |
| 0.5 mg | 0.2 mL | 20 units |
| 1.0 mg | 0.4 mL | 40 units |
| 1.7 mg | 0.68 mL | 68 units |
| 2.4 mg | 0.96 mL | 96 units |
Administration Tips
- Inject subcutaneously in the abdomen, thigh, or upper arm
- Rotate injection sites to prevent lipodystrophy
- Inject on the same day each week at any time of day
- Store reconstituted solution in the refrigerator and use within 28 days
Risks & Side Effects
Commonly Reported
Serious Risks
Pancreatitis
Inflammation of the pancreas; discontinue use if suspected.
Gallbladder problems
Including gallstones and cholecystitis.
Kidney injury
Usually related to dehydration from gastrointestinal side effects.
Hypoglycemia
Especially when combined with other diabetes medications.
Allergic reactions
Including anaphylaxis in rare cases.
Thyroid C-cell tumors
Semaglutide carries a boxed warning for risk of thyroid C-cell tumors based on animal studies; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
- Pregnancy or breastfeeding
Frequently Asked Questions
Related Peptides
Experts Covering Semaglutide
Dr. William A. Seeds
MD -- Regenerative Medicine Pioneer
Dr. Andrew Huberman
PhD -- Stanford Neuroscientist
Jay Campbell
Health Optimization Author and Peptide Advocate
Dr. Ian W. Hamley
Diamond Professor of Physical Chemistry -- University of Reading
Matthew Farrahi
Biohacker, CEO of Sigma Compounds, and Fitness Creator
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.